# Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL

> **NCT01148134** · — · TERMINATED · sponsor: **University Health Network, Toronto** · enrollment: 10 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01148134
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Analysis of the first 10 patients did not show anyt trend toward differences in PK profiles between imatinib vs no imatinib groups.
- **Last updated:** 2013-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01148134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01148134, "Pharmacokinetic Profile of Vincristine Administered With Imatinib for Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) Compared to That Without Imatinib for Bcr-Abl Negative ALL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01148134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*